I.)....ADE (Antibody Dependent Enhancement)
1.) Geert Vanden Bossche’s open letter warning that current measures (social distancing and "leaky" vaccines) will worsen the pandemic
"Why mass vaccination amidst a pandemic creates an irrepressible monster"
https://37b32f5a-6ed9-4d6d-b3e1-5ec648ad9ed9.filesusr.com/ugd/28d8fe_266039aeb27a4465988c37adec9cd1dc.pdf
2.) Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination?
"ADE may occur in people receiving vaccines based on the original Wuhan strain spike sequence (either mRNA or viral vectors) and then exposed to a Delta variant."
doi:10.1016/j.jinf.2021.08.010
3.) How Innate Immune Mechanisms Contribute to Antibody-Enhanced Viral Infections
"Preexisting antibodies may enhance viral infections. In dengue, non-neutralizing antibodies raised by natural infection with one of four dengue viruses (DENVs) may enhance infection with a different virus by a process we term intrinsic antibody-dependent enhancement (iADE)."
doi:10.1128/CVI.00316-10
4.) Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
"Safety concerns for SARS-CoV-2 vaccines were initially fueled by mouse studies that showed enhanced immunopathology, or ERD, in animals vaccinated with SARS-CoV following viral challenge"
doi:10.1038/s41564-020-00789-5
II.)....Children and Young People
1.) SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis
"For boys 12-15 without medical comorbidities receiving their second mRNA vaccination dose, the rate of Cardiac Adverse Event (CAE) is 3.7 to 6.1 times higher than their 120-day COVID-19 hospitalization risk and 2.6-4.3-fold higher at times of high weekly hospitalization risk. For boys 16-17 without medical comorbidities, the rate of CAE is currently 2.1 to 3.5 times higher than their 120-day COVID-19 hospitalization risk, and 1.5 to 2.5 times higher at times of high weekly COVID-19 hospitalization."
doi:10.1101/2021.08.30.21262866
2.) Age-specific mortality and immunity patterns of SARS-CoV-2
"We estimate that the infection fatality ratio is lowest among 5-9-year-old children, with a log-linear increase by age among individuals older than 30 years."
doi:10.1038/s41586-020-2918-0
3.) Deaths in Children and Young People in England following SARS-CoV-2 infection during the first pandemic year: a national study using linked mandatory child death reporting data
"99.995% of CYP with a positive SARS-CoV-2 test survived. The 25 CYP who died of SARS-CoV-2 equates to a mortality rate of 2/million for the 12,023,568 CYP living in England."
doi:/10.21203/rs.3.rs-689684/v1
4.) JCVI issues updated advice on COVID-19 vaccination of children aged 12 to 15
"The assessment by the Joint Committee on Vaccination and Immunisation (JCVI) is that the health benefits from vaccination are marginally greater than the potential known harms. However, the margin of benefit is considered too small to support universal vaccination of healthy 12 to 15 year olds at this time."
https://www.gov.uk/government/news/jcvi-issues-updated-advice-on-covid-19-vaccination-of-children-aged-12-to-15
5.) Why Parents, Teens, and Children Should Question the COVID-19 Vaccine Canadian Covid Care Alliance
"As of May 28, 2021, there have been 259,308 confirmed cases of SARS-CoV-2 infections in Canadians 19 years and under. Of these, 0.048% were hospitalized, 0.06% were admitted to ICU, and 0.004% died1. Seasonal influenza is associated with more severe illness than COVID-19."
https://www.canadiancovidcarealliance.org/wp-content/uploads/2021/06/Guide_to_COVID19_vaccines_for_parents_v5.pdf
6.) For COVID or With COVID?: Classification of SARS-CoV-2 Hospitalizations in Children
"Our findings demonstrate that most children hospitalized with SARS-CoV-2 have asymptomatic or mild/moderate disease, and nearly half of these hospitalizations were not caused by infection from the virus itself."
doi:10.1542/hpeds.2021-006001
7.) Risk factors for intensive care admission and death amongst children and young people admitted to hospital with COVID-19 and PIMS-TS in England during the first pandemic year
"We found extremely low numbers of CYP required PICU or died as a result of SARS-CoV-2 in the first pandemic year. CYP admitted due to COVID-19 disease were older and more likely to be non-white with pre-existing conditions, similar to patterns seen in adults."
doi:/10.1101/2021.07.01.21259785
8.) Myocarditis and Pericarditis Following Vaccination with COVID-19 mRNA Vaccines in Ontario: December 13, 2020 to August 7, 2021
"The number of reported events of myocarditis/pericarditis began to increase in early June of 2021. This period of time coincided with increased vaccine supply (particularly of Moderna), administration of second doses, program expansion to younger age groups, and release of the ESD"
https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-myocarditis-pericarditis-vaccines-epi.pdf?sc_lang=en
9.) Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military
"In this case series, myocarditis occurred in previously healthy military patients with similar clinical presentations following receipt of an mRNA COVID-19 vaccine."
doi:10.1001/jamacardio.2021.2833
10.) COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years United States, December 14, 2020 July 16, 2021 (CDC)
"Overall, 8,383 (90.7%) VAERS reports were for nonserious events, and 863 (9.3%) for serious events, including death; 609 (70.6%) reports of serious events were among males, and median age was 15 years. The most commonly reported conditions and diagnostic findings among reports of serious events were chest pain (56.4%), increased troponin levels (41.7%), myocarditis (40.3%), increased c-reactive protein (30.6%)"
https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7031e1-H.pdf
III.)....Effectiveness of the Vaccines
1.) Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence
"However, in July, the effectiveness against infection was considerably lower for mRNA-1273 (76%, 95% CI: 58-87%) with an even more pronounced reduction in effectiveness for BNT162b2 (42%, 95% CI: 13-62%)."
doi:10.1101/2021.08.06.21261707
2.) Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021
"Approximately three quarters (346; 74%) of cases occurred in fully vaccinated persons (those who had completed a 2-dose course of mRNA vaccine [Pfizer-BioNTech or Moderna] or had received a single dose of Janssen [Johnson & Johnson] vaccine 14 days before exposure)."
doi:10.15585/mmwr.mm7031e2
3.) Correlation of SARS-CoV-2 Breakthrough Infections to Time-from-vaccine; Preliminary Study
"We found that the risk for infection was significantly higher for early vaccinees compared to those vaccinated later."
doi:10.1101/2021.07.29.21261317
4.) COVID-19 Vaccines May Not Prevent Nasal SARS-CoV-2 Infection and Asymptomatic Transmission
"This suggests that systemically vaccinated patients, while asymptomatic, may still be become infected and transmit live virus from the upper airway."
doi:10.1177/0194599820982633
5.) Public health investigations of COVID-19 vaccine breakthrough cases (CDC)
"a vaccine breakthrough case will be defined as a U.S. resident who has SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected 14 days after completing the primary series of an FDA-authorized SARS-CoV-2 vaccine."
https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html
6.) COVID-19 vaccine efficacy and effectiveness, the elephant (not) in the room
"These considerations on efficacy and effectiveness are based on studies measuring prevention of mild to moderate COVID-19 infection; they were not designed to conclude on prevention of hospitalization, severe disease, or death, or on prevention of infection and transmission potential."
doi:10.1016/S2666-5247(21)00069-0
7.) Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
"We found that the effectiveness of BNT162b2 and ChAd0x1 against any infections (new PCR positives) and infections with symptoms or high viral burden is reduced with the Delta variant."
doi:/10.1101/2021.08.18.21262237
8.) Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam
"Breakthrough Delta variant infections are associated with high viral loads, prolonged PCR positivity, and low levels of vaccine-induced neutralizing antibodies, explaining the transmission between the vaccinated people."
doi:/10.2139/ssrn.3897733
9.) Vaccinated and unvaccinated individuals have similar viral loads in communities with a high prevalence of the SARS-CoV-2 delta variant
"Considering all 291 samples from all counties, there were 79 infections among individuals who were fully vaccinated. Sixty-six of these 79 (84%) had Ct values <30, while 177 of 212 (83%) unvaccinated individuals had viral loads in this range."
doi:/10.1101/2021.07.31.21261387
10.) Does the FDA think these data justify the first full approval of a covid-19 vaccine?
"The concern, of course, was decreased efficacy over time. “Waning immunity” is a known problem for influenza vaccines, with some studies showing near zero effectiveness after just three months, meaning a vaccine taken early may ultimately provide no protection by the time flu season arrives some months later."
https://blogs.bmj.com/bmj/2021/08/23/does-the-fda-think-these-data-justify-the-first-full-approval-of-a-covid-19-vaccine/
IV.)....Side Effects
1.) Pfizer Bio-Distribution Japanese Study (Pfizer Confidential)
"When the radioactivity-labeled body of ZeRNA-encapsulated LNP was intramuscularly administered, the radioactivity concentration was the highest at the administration site. Other than the site of administration, it was highest in the liver, followed by the spleen, adrenal glands and ovaries."
https://rightsfreedoms.wordpress.com/2021/06/03/confidential-pfizer-research-document/
2.) Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?
"The vaccine contains a number of excipients and lipids, one of them based on PEG-2000. This is currently the only excipient in the vaccine with recognized allergenic potential. The severity and rapid onset of the two reported reactions to the vaccine further increase suspicion towards PEG."
doi:10.1016/j.bja.2020.12.020
3.) Lipid nanoparticles for mRNA delivery
"Lipid components may activate host immune responses following systemic or local administration; for example, PEG-lipids could induce hypersensitivity reactions by stimulating the complement system"
doi:10.1038/s41578-021-00358-0
4.) Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting (pfizer)
"Vaccination was most strongly associated with an elevated risk of myocarditis, lymphadenopathy, appendicitis, and herpes zoster infection"
doi:10.1056/NEJMoa2110475
5.) The Safety of COVID-19 Vaccinations. We Should Rethink the Policy (Retracted)
"For three deaths prevented by vaccination we have to accept two inflicted by vaccination. Conclusions: This lack of clear benefit should cause governments to rethink their vaccination policy."
doi:10.3390/vaccines9070693
6.) Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study
"Increased risks of haematological and vascular events that led to hospital admission or death were observed for short time intervals after first doses of the ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines."
doi:10.1136/bmj.n1931
7.) Myocarditis and Pericarditis After Vaccination for COVID-19
"The Centers for Disease Control and Prevention recently reported a possible association between COVID-19 mRNA vaccines and myocarditis, primarily in younger male individuals. This study shows a similar pattern, although at higher incidence, suggesting vaccine adverse event underreporting. Additionally, pericarditis may be more common than myocarditis among older patients."
doi:10.1001/jama.2021.13443
8.) Pfizer-BioNTech COVID-19 Vaccine EUA Fact Sheet for Healthcare Providers
"Available data on Pfizer-BioNTech COVID-19 Vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. Data are not available to assess the effects of Pfizer-BioNTech COVID-19 Vaccine on the breastfed infant or on milk production/excretion."
https://www.fda.gov/media/144413/download
9.) COVID-19 mRNA Pfizer- BioNTech vaccine analysis print
-a list of side effects-
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1018450/Pfizer.pdf
10.) COVID-19 vaccine AstraZeneca analysis print
-a list of side effects-
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1018451/AZ.pdf
11.) COVID-19 Moderna vaccine analysis print
-a list of side effects-
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1018452/Moderna.pdf
12.) COVID-19 vaccine brand unspecified analysis print
-a list of side effects-
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1018453/Brand_unspecified.pdf
13.) Coronavirus vaccine - weekly summary of Yellow Card reporting 9 December 2020 to 8 September 2021
-a list of side effects
https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting
V.)....Natural Immunity
1.) Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel
"This study suggests that both the BNT162b2 vaccine and prior SARS-CoV-2 infection are effective against both subsequent SARS-CoV-2 infection and other COVID-19 related outcomes. Moreover, the effectiveness seems similar for both cohorts. This puts into question the need to vaccinate recent (up to six month) previously-infected individuals."
doi:10.1101/2021.04.20.21255670
2.) Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study
"Protection against repeat infection was 80.5%. The alternative cohort analysis gave similar estimates, estimated protection 78.8%."
doi:10.1016/S0140-6736(21)00575-4
3.) Quantifying the risk of SARS CoV-2 reinfection over time
"Reinfection was an uncommon event (absolute rate 0%-1.1%), with no study reporting an increase in the risk of reinfection over time. Only one study estimated the population level risk of reinfection based on whole genome sequencing in a subset of patients; the estimated risk was low (0.1%) with no evidence of waning immunity for up to 7 months following primary infection."
doi:10.1002/rmv.2260
4.) SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks
"Incidence rate of reinfection versus month of follow-up did not show any evidence of waning of immunity for over seven months of follow-up. Efficacy of natural infection against reinfection was estimated at >90%. Reinfections were less severe than primary infections"
doi:10.1101/2021.01.15.21249731
5.) Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
"Overall, we found that strong and broad T cell memory responses were induced after recovery from COVID-19, and the breadth and magnitude of T cell responses were significantly higher in severe compared with mild cases."
doi:10.1038/s41590-020-0782-6
6.) Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections
"SARS-CoV-2-naive vaccinees had a 13.06-fold (95% CI, 8.08 to 21.11) increased risk for breakthrough infection with the Delta variant compared to those previously infected, when the first event (infection or vaccination) occurred during January and February of 2021."
doi:10.1101/2021.08.24.21262415
7.) Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination
"Initially, it was assumed that SARS-CoV-2 encountered an immunologically unprotected population, however, SARS-CoV-2 displays considerable homologies with endemic, seasonal common cold endemic coronaviruses (collectively referred to as HcoV)."
doi:10.1101/2021.04.01.21252379
8.) Rapid and lasting generation of B-cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 disease and convalescence
"RBD- and NCP-specific Bmem cells persisted for 8 months, indicating that the decline in serum antibodies after 1 month does not indicate waning of immunity but a contraction of the immune response."
doi:10.1101/2020.11.17.20233544
9.) A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection
"The protective effect of prior SARS-CoV-2 infection on re-infection is high and similar to the protective effect of vaccination"
doi:10.1101/2021.08.27.21262741
10.) Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
"Individual case reports show that reinfections with SARS-CoV-2 are occurring. However, a 2,800 person study found no symptomatic re-infections over a ~118 day window, and a 1,246 person study observed no symptomatic re-infections over 6 months"
doi:10.1126/science.abf4063
11.) SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans
"Long-lived bone marrow plasma cells (BMPCs) are a persistent and essential source of protective antibodies. Individuals who have recovered from COVID-19 have a substantially lower risk of reinfection with SARS-CoV-2"
doi:/10.1038/s41586-021-03647-4
12.) Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
"In the absence of vaccination, antibody reactivity to the receptor binding domain (RBD) of SARS-CoV-2, neutralizing activity and the number of RBD-specifc memory B cells remain relatively stable between 6 and 12 months after infection."
doi:10.1038/s41586-021-03696-9
13.) Necessity of COVID-19 vaccination in previously infected individuals
"Cumulative incidence of COVID-19 was examined among 52238 employees in an American healthcare system. COVID-19 did not occur in anyone over the five months of the study among 2579 individuals previously infected with COVID-19, including 1359 who did not take the vaccine."
doi:10.1101/2021.06.01.21258176
14.) SARS-CoV-2-specific T cell memory is long-lasting in the majority of convalsecent COVID-19 individuals
"Being situated in Wuhan where the pandemic initiated enables us to conduct the longest analyses of memory T cell responses in COVID-19 convalescent individuals (CIs). Magnitude and breadth of SARS-CoV-2 memory CD4 and CD8 T cell responses were heterogeneous between patients but robust responses could be detected up to 9 months post disease onset in most Cis."
doi:10.1101/2020.11.15.383463
VI.)....PCR Test
1.) Correlation Between 3790 Quantitative Polymerase Chain Reaction-Positives Samples and Positive Cell Cultures, Including 1941 Severe Acute Respiratory Syndrome Coronavirus 2 Isolates
"It can be observed that at Ct = 25, up to 70% of patients remain positive in culture and that at Ct = 30 this value drops to 20%. At Ct = 35, the value we used to report a positive result for PCR, <3% of cultures are positive"
doi:10.1093/cid/ciaa1491
2.) External peer review of the RTPCR test to detect SARS-CoV-2 reveals 10 major scientific flaws at the molecular and methodological level: consequences for false positive results
"This paper will show numerous serious flaws in the Corman-Drosten paper, the significance of which has led to worldwide misdiagnosis of infections attributed to SARS-CoV-2 and associated with the disease COVID-19."
doi:10.5281/zenodo.4298004
VII.)....Masks and Social Distancing
1.) Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers
"The recommendation to wear surgical masks to supplement other public health measures did not reduce the SARS-CoV-2 infection rate among wearers by more than 50% in a community with modest infection rates, some degree of social distancing, and uncommon general mask use."
doi:10.7326/M20-6817
2.) The Failure of Imperial College Modeling Is Far Worse than We Knew
"Ferguson predicted catastrophic death tolls back on March 16, 2020 unless governments around the world adopted his preferred suite of nonpharmaceutical interventions (NPIs) to ward off the pandemic."
https://www.aier.org/article/the-failure-of-imperial-college-modeling-is-far-worse-than-we-knew/
3.) Using face masks in the community: first update Effectiveness in reducing transmission of COVID-19 (ECDC)
"The evidence regarding the effectiveness of medical face masks for the prevention of COVID-19 in the community is compatible with a small to moderate protective effect, but there are still significant uncertainties about the size of this effect. Evidence for the effectiveness of non-medical face masks, face shields/visors and respirators in the community is scarce and of very low certainty."
https://www.ecdc.europa.eu/en/publications-data/using-face-masks-community-reducing-covid-19-transmission
4.) Facemask against viral respiratory infections among Hajj pilgrims: A challenging cluster-randomized trial
"This trial was unable to provide conclusive evidence on facemask efficacy against viral respiratory infections most likely due to poor adherence to protocol."
doi:10.1371/journal.pone.0240287
5.) Mask mandate and use efficacy in state-level COVID-19 containment
"Case growth was not significantly different between mandate and non-mandate states at low or high transmission rates, and surges were equivocal. Mask use predicted lower case growth at low, but not high transmission rates."
doi:10.1101/2021.05.18.21257385
6.) A guideline to limit indoor airborne transmission of COVID-19
"Above all, our study makes clear the inadequacy of the Six-Foot Rule in mitigating indoor airborne disease transmission, and offers a rational, physically informed alternative for managing life in the time of COVID-19."
doi:10.1073/pnas.2018995118
VIII.)....Treatment of COVID
1.) Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection
"It is conceivable that some, if not a majority, of hospitalizations could be avoided with a treat-at-home first approach with appropriate telemedicine monitoring and access to oxygen and therapeutics."
doi:10.1016/j.amjmed.2020.07.003
2.) The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article
"Considering the urgency of the ongoing COVID-19 pandemic, simultaneous detection of various new mutant strains and future potential re-emergence of novel coronaviruses, repurposing of approved drugs such as Ivermectin could be worthy of attention."
doi:10.1038/s41429-021-00430-5
3.) Ivermectin for Prevention and Treatment of COVID-19 Infection: a Systematic Review and Meta-analysis
"Meta-analysis of 13 trials, assessing 1892 participants, found that ivermectin reduced the risk of death by an average of 68% (95% CI, 28-86%) compared with no ivermectin treatment"
doi:10.21203/rs.3.rs-317485/v1
4.) Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2
"The ivermectin docking we identified may interfere with the attachment of the spike to the human cell membrane."
doi:10.21873/invivo.12134
5.) Expert Review Report Medical Safety Of Ivermectin - medincell (requires email)
"Taking into account all the above, the author of the present analysis of the available medical data concludes that the safety profile of ivermectin has so far been excellent in the majority of treated human patients so that ivermectin human toxicity cannot be claimed to be a serious cause for concern"
https://www.medincell.com/ivermectin/
6.) Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database
"The most often specifically reported effects were acute kidney injury (48.6%), blood creatinine increased (32.6%), renal impairment (11.6%), glomerular filtration rate (GFR) decreased (10.9%), renal failure (9.4%), dialysis (5.1%), and renal tubular necrosis (3.6%)"
doi:/10.1002/cpt.2145
IX.)....Spike Protein
1.) SARS-CoV-2 Spike Protein Induces Paracrine Senescence and Leukocyte Adhesion in Endothelial Cells
"Increased mortality in COVID-19 cases is often associated with microvascular complications. We have recently shown that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein promotes an inflammatory cytokine interleukin 6 (IL-6)/IL-6R-induced trans signaling response and alarmin secretion."
doi:10.1128/JVI.00794-21
2.) S2 Subunit of SARS-nCoV-2 Interacts with Tumor Suppressor Protein p53 and BRCA: an In Silico Study
"Here we performed bioinformatic analysis to investigate the interaction of S2 subunit protein of SARS-nCoV-2 of novel coronavirus with tumor suppressor proteins p53 and BRCA-1/2."
doi:10.1016/j.tranon.2020.100814
3.) The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice
"We show that intravenously injected radioiodinated S1 (I-S1) readily crossed the blood-brain barrier in male mice, was taken up by brain regions and entered the parenchymal brain space. I-S1 was also taken up by the lung, spleen, kidney and liver."
doi:10.1038/s41593-020-00771-8
4.) The SARS-CoV-2 spike protein subunit S1 induces COVID-19-like acute lung injury in K18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells
"we intratracheally instilled the S1 subunit of SARS-CoV-2 spike protein (S1SP) in K18-hACE2 transgenic mice that overexpress human ACE2 and examined signs of COVID-19-associated lung injury 72 h later"
doi:10.1152/ajplung.00223.2021
5.) SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2
"In the current study, we show that S protein alone can damage vascular endothelial cells (ECs) by downregulating ACE2 and consequently inhibiting mitochondrial function"
doi:10.1161/CIRCRESAHA.121.318902
6.) Circulating SARS-CoV-2 Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients (moderna)
"After the first 100 Aµg dose, the mRNA-1273 vaccine produced detectable levels of S1 antigen in plasma in 11 participants and spike antigen was detected in three of 13 participants."
doi:10.1093/cid/ciab465
X.)....Further Questions
1.) Wodarg - Yeadon Petition to Stop Phase III trial of BNT162 (pfizer)
"Thus, it is reasonable to suspect that COVID-19 vaccines, including the Pfizer vaccine, could become mandatory. Without the FDA assuring proper efficacy trials of the vaccine now, the Petitioner and the public may not have the opportunity to object to receiving the vaccine, which was approved based on currently deficient and unreliable clinical trial data."
https://dokumen.pub/wodarg-yeadon-covid-19-vaccine-petition.html
2.) Playing vaccine roulette: Why the current strategy of staking everything on Covid-19 vaccines is a high-stakes wager
"The current strategy of staking everything on vaccines, without sufficient hindsight on its risk-benefit ratio, and at the expense of complementary strategies (treatment, health system strengthening, non-pharmaceutical prevention, promotion of safe conditions that prevent transmission, and healthy lifestyles), was and may still remain insufficient, reactive, short-sighted, and an unnecessary high-stakes wager that is tempting fortune."
doi:10.1016/j.vaccine.2021.07.045
3.) Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus
"However, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARS-CoV components was induced. Caution in proceeding to application of a SARS-CoV vaccine in humans is indicated."
doi:10.1371/journal.pone.0035421
4.) Ventegodt, Merrick : A tribute to the Corona virus COVID-19 (SARS-CoV-2) whistle-blowers
"WHO exaggerates the mortality 340 times, saying the COVID-19 has a mortality rate of 3.4%. This high number comes from the case fatality rate, which has nothing to do with the mortality rate"
https://www.researchgate.net/publication/341298531_A_tribute_to_the_Corona_virus_COVID-19_SARS-CoV-2_whistle-blowers
5.) Worse Than the Disease? Reviewing Some Possible Unintended Consequences of the mRNA Vaccines Against COVID-19 - JVTPR [very interesting!]
"technology underlying these vaccines in detail / production of the spike protein and their potential relationship to a wide range of both acute and long-term induced pathologies / relevance of prion-protein-related amino acid sequences within the spike protein / spike protein “shedding” / whether or not these vaccines could modify the DNA of those receiving the vaccination."
https://dpbh.nv.gov/uploadedFiles/dpbhnvgov/content/Boards/BOH/Meetings/2021/SENEFF~1.PDF
6.) Risk factors for long COVID: analyses of 10 longitudinal studies and electronic health records in the UK
"Functionally limiting long COVID for 12+ weeks affected between 1.2% (age 20), and 4.8% (age 63) of people reporting COVID-19 in LS."
doi:/10.1101/2021.06.24.21259277
7.) Great Barrington Declaration
"As infectious disease epidemiologists and public health scientists we have grave concerns about the damaging physical and mental health impacts of the prevailing COVID-19 policies, and recommend an approach we call Focused Protection."
https://gbdeclaration.org
XI.)....Origins of COVID (?)
1.) Project DEFUSE
"A brief DRASTIC Analysis of the EcoHealth Alliance DEFUSE Proposal"
https://drasticresearch.files.wordpress.com/2021/09/defuse-project-drastic-analysis-1.pdf
2.) Rejection of DEFUSE Project Proposal
https://drasticresearch.files.wordpress.com/2021/09/defuse-project-rejection-by-darpa.pdf
3.) The COVID Network Complex
https://clubderklarenworte.de/wp-content/uploads/2021/09/Netzwerkanalyse-Corona-Komplex.pdf
How to search VAERS (Vaccine Adverse Event Reporting System)
Go to: https://wonder.cdc.gov/vaers.html
1.) Agree to the disclaimer at the bottom of the page
2.) In the upper left corner select "Request Form"
3.) In section 1 (Organize table layout:) select "Year Reported"
4.) In section 5 (Select other event characteristics:) select "Death"
5.) Press "Send"
2.) In the upper left corner select "Request Form"
3.) In section 1 (Organize table layout:) select "Year Reported"
4.) In section 5 (Select other event characteristics:) select "Death"
5.) Press "Send"
Also see:
Dr. Mike Yeadon former Pfizer CEO
Dr. Robert Malone inventor of mRNA vax
Dr. Kary Mullis inventor of PCR test
Dr. Sucharit Bhakdi
Dr. David Martin
Dr. Geert Vanden Bossche
Dr. Suneel Dhand
Dr. Peter McCullough
Dr. Joseph Mercola
Dr. Luc Montagnier
Dr. Keith Moran
Dr. Martin Kulldorff
Dr. Marty Makary
Dr. Paul E. Marik
Dr. Vernon Coleman
Dr. Andrew Kaufman
Dr. Martin Feeley
Dr. Harvey Risch
Dr. Byram Bridle
Dr. Roger Hodkinson
Dr. Tom Cowan
Dr. Stefan Lanka
Reiner Fuellmich (lawyer)
Dr. Robert Malone inventor of mRNA vax
Dr. Kary Mullis inventor of PCR test
Dr. Sucharit Bhakdi
Dr. David Martin
Dr. Geert Vanden Bossche
Dr. Suneel Dhand
Dr. Peter McCullough
Dr. Joseph Mercola
Dr. Luc Montagnier
Dr. Keith Moran
Dr. Martin Kulldorff
Dr. Marty Makary
Dr. Paul E. Marik
Dr. Vernon Coleman
Dr. Andrew Kaufman
Dr. Martin Feeley
Dr. Harvey Risch
Dr. Byram Bridle
Dr. Roger Hodkinson
Dr. Tom Cowan
Dr. Stefan Lanka
Reiner Fuellmich (lawyer)
